VICKI L. SATO - 01 Jul 2024 Form 4 Insider Report for Denali Therapeutics Inc. (DNLI)

Role
Director
Signature
/s/ Tyler Nielsen, by power of attorney
Issuer symbol
DNLI
Transactions as of
01 Jul 2024
Net transactions value
-$68,204
Form type
4
Filing time
03 Jul 2024, 21:13:04 UTC
Previous filing
07 Jun 2024
Next filing
04 Sep 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction DNLI Common Stock Sale $65,918 -2,980 -2.4% $22.12 119,356 01 Jul 2024 Direct F1, F2, F3
transaction DNLI Common Stock Sale $2,286 -100 -0.08% $22.86 119,256 01 Jul 2024 Direct F1, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan adopted March 21, 2024.
F2 The sale price reported in column 4 of Table I represents the weighted average sale price of the shares ranging from $21.86 to $22.83 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
F3 Includes 5,967 unvested RSUs.